CN114848615A - 和厚朴酚小分子自主装纳米粒及制备方法 - Google Patents
和厚朴酚小分子自主装纳米粒及制备方法 Download PDFInfo
- Publication number
- CN114848615A CN114848615A CN202210539715.9A CN202210539715A CN114848615A CN 114848615 A CN114848615 A CN 114848615A CN 202210539715 A CN202210539715 A CN 202210539715A CN 114848615 A CN114848615 A CN 114848615A
- Authority
- CN
- China
- Prior art keywords
- honokiol
- preparation
- nanoparticles
- small
- molecule self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 title claims abstract description 53
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 31
- -1 Honokiol small-molecule Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000008367 deionised water Substances 0.000 claims abstract description 12
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 12
- 238000000502 dialysis Methods 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000001338 self-assembly Methods 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 238000011068 loading method Methods 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 25
- 238000012360 testing method Methods 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了和厚朴酚小分子自主装纳米粒及制备方法,其制备方法为:将和厚朴酚溶解于pH=10‑12的碱水溶液中,在70‑80℃搅拌50‑70分钟;转入到透析袋中,在去离子水中透析8‑24小时,每1‑2小时换去离子水一次,除去游离的和厚朴酚;收集透析袋内液体,干燥,获得和厚朴酚小分子自主装纳米粒。实验结果证明,本发明的和厚朴酚小分子自主装纳米粒具有百分之百的载药量,组织分布充分,且无明显毒副作用,能够显著抑制癌细胞的增殖和诱导癌细胞的凋亡,由于EPR效应,和厚朴酚小分子自主装纳米粒的抑制癌细胞的效果优于有游离的和厚朴酚。
Description
技术领域
本发明涉及医药技术领域,具体涉及和厚朴酚小分子自主装纳米粒及制备方法及在制备抗癌药中的应用。
背景技术
天然产物为抗癌药物的发展做出了巨大贡献。据报道,超过48.6%的抗癌药物是天然产物的仿制品,或天然产物的直接用途。和厚朴酚是中药厚朴的主要有效成分。1985年Kuttan等首次提出和厚朴酚可以治疗肿瘤,随后大量的研究证明和厚朴酚具有抗感染、抗炎、抗氧化、抑制肿瘤生长等作用,因其具有广谱抗癌、高效、低毒等特点,已经被称为第3代抗癌药物。而随着肿瘤发病率的不断增高,和厚朴酚抗肿瘤活性备受关注。
脂质体包裹和厚朴酚治疗晚期非小细胞肺癌的一期临床试验(CTR20170822)目前正在中国进行。但其存在稳定性低、水溶性差、生物利用度低以及体内代谢迅速等缺陷,极大地限制了其临床开发。为了克服上述缺点并提高抗肿瘤活性,有研究开发了几种具有较高体内外抗癌活性的和厚朴酚(HK)纳米粒子。例如两亲性PEG-PCL PEG-PLA、环糊精、石墨烯、牛血清白蛋白(BSA)、和pluronic F127,但这些纳米颗粒仍存在许多局限性,如载药量不理想、组织分布不充分以及潜在的毒性等。
发明内容
本发明的目的是克服现有技术的不足,提供一种和厚朴酚小分子自主装纳米粒。
本发明的第二个目的是提供一种和厚朴酚小分子自主装纳米粒的制备方法。
本发明的第三个目的是提供一种和厚朴酚小分子自主装纳米粒在制备抗癌药中的应用。
本发明的第四个目的是提供一种包含上述和厚朴酚小分子自主装纳米粒的制剂。
本发明的技术方案概述如下:
和厚朴酚小分子自主装纳米粒的制备方法,包括以下步骤:将和厚朴酚溶解于pH=10-12的碱水溶液中,在70-80℃搅拌50-70分钟;转入到透析袋中,在去离子水中透析8-24小时,每1-2小时换去离子水一次,除去游离的和厚朴酚;收集透析袋内液体,干燥,获得和厚朴酚小分子自主装纳米粒。
碱优选为NaOH或KOH。
上述制备方法制备的和厚朴酚小分子自主装纳米粒。
上述和厚朴酚小分子自主装纳米粒在制备抗癌药中的应用。
包含和厚朴酚小分子自主装纳米粒的制剂。
所述制剂的剂型为注射剂、片剂、胶囊剂、滴丸剂或软膏剂。
本发明的优点:
实验结果证明,本发明的和厚朴酚小分子自主装纳米粒具有百分之百的载药量,组织分布充分,且无明显毒副作用,能够显著抑制癌细胞的增殖和诱导癌细胞的凋亡,由于EPR效应,和厚朴酚小分子自主装纳米粒的抑制癌细胞的效果优于有游离的和厚朴酚。
附图说明
图1为SA粒径分布图。
图2为形貌表征图。
图3为SA体内抗肿瘤的作用。
具体实施方式
和厚朴酚(Gibco),胎牛血清(大连美伦)。
人结肠癌细胞HT-29细胞(ATCC)于2019年8月购买,大连美伦,中国、联系方式400-650-3656。
下面结合具体实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
和厚朴酚小分子自主装纳米粒(Self assembly,简称SA)的制备方法,包括以下步骤:将和厚朴酚(HK)溶解于pH=11的NaOH水溶液中,在75℃搅拌60分钟;转入到透析袋中,在去离子水中透析12小时,每1.5小时换去离子水一次,除去游离的和厚朴酚;收集透析袋内液体,干燥,获得和厚朴酚小分子自主装纳米粒。
和厚朴酚小分子自主装纳米粒在水中的分布,见图1。
SA的表征:
1、试验仪器
扫描电子显微镜(SEM,LEO1530VP,卡尔蔡司公司,德国)和透射电子显微镜(TEM,JEM2100,日本JEOL)观察形貌。Malvern Zetasizer纳米ZS的动态光散射(DLS)。PerkinElmer a Cary 60紫外-可见分光光度计(美国加利福尼亚州圣克拉拉市安捷伦科技公司)。
荧光光谱由荧光光谱仪(Horiba,fluoromax-4,美国)检测。Bruker IFS-55红外光谱仪(FT-IR)。
2、进行SEM和TEM;
3、试验结果
由SEM和TEM证实的SA形态结果见图2A和图2B。SEM结果(图2A)显示,SA可以很好地分布在水中,SA在水中呈球形,直径约为80-100纳米。HK在水中形成浑浊的白色浆液,HK的SEM(图2C)以不规则的块状存在,颗粒大小从大约10.29微米到30.34微米不等。图2D所示,SA有明显的丁达尔效应,表明HK可以自发组装形成纳米粒。
实施例2
和厚朴酚小分子自主装纳米粒的制备方法,包括以下步骤:将和厚朴酚溶解于pH=10的NaOH水溶液中,在70℃搅拌70分钟;转入到透析袋中,在去离子水中透析8小时,每1小时换去离子水一次,除去游离的和厚朴酚;收集透析袋内液体,干燥,获得和厚朴酚小分子自主装纳米粒。
实施例3
和厚朴酚小分子自主装纳米粒的制备方法,包括以下步骤:将和厚朴酚溶解于pH=12的KOH水溶液中,在80℃搅拌50分钟;转入到透析袋中,在去离子水中透析24小时,每2小时换去离子水一次,除去游离的和厚朴酚;收集透析袋内液体,干燥,获得和厚朴酚小分子自主装纳米粒。
实验证明,实施例2、实施例3制备获得的SA在水中的分布与实施例1获得的SA在水中的分布相似。
实施例2、实施例3的SEM与实施例1获得的SEM结果相似。
实施例2、实施例3的TEM结果与实施例1获得的TEM结果相似。
实施例4
SA对人结直肠癌细胞HT-29增殖的影响
1、试验试剂
DMSO(BD),PBS(PH=7.2-7.4,BD),MTT(BD)(5mg/mL),DMEM培养基(Gibco),胎牛血清(大连美伦)。
3、试验方法
将处于对数生长期的肿瘤细胞接种于96孔板中,培养过夜,待细胞生长贴壁后(一般为12-24h后),分别加入一定浓度梯度(2μM,5μM,10μM)的SA(实施例1制备),每个浓度设3个复孔。在5%CO2、37℃的细胞培养箱中培养24h后,倾去培养液,向每孔加入10μl的CCK8溶液(市售)和90μl培养液(注意不要产生气泡),将培养板置于培养箱中2h后,用酶标仪在450nm波长下测定吸光度(OD值)。按照吸光度OD值计算抑制率:抑制率(%)=(OD对照-OD给药-OD空白)/(OD对照-OD空白)×100%。运用Graphpad Prism 9.0软件计算半数抑制率IC50。
5、试验结果
CCK8结果表明SA对HT-29(人结直肠癌细胞)IC50值为17.10μM。
实验证明,实施例2、实施例3制备获得的SA半数抑制率IC50与实施例1获得的SA半数抑制率IC50相似。
实施例5
SA(实施例1制备)对HT-29(人结直肠癌细胞)的细胞凋亡试验
1、试验方法
取对数生长期的细胞HT-29,分别用胰蛋白酶消化并吹打成单个细胞,并把细胞悬浮在10%胎牛血清的DMEM培养液中备用。将细胞悬液作梯度倍数稀释,每组细胞分别以每皿105个细胞的梯度密度分别接种于六孔板中,并轻轻转动,使细胞分散均匀。置37℃5%CO2及饱和湿度的细胞培养箱中培养。次日加入相应浓度的药液作用48h后,细胞消化离心收集到10ml的离心管中,每样本细胞数为(1-5)x106/ml。1000r/min离心3min,弃去培养液。按照试剂盒进行操作后上机检测。
2、试验结果
SA对HT-29细胞凋亡的结果表1所示。
表1 HT-29细胞凋亡结果
实验证明,实施例2、实施例3制备获得的SA对HT-29的细胞凋亡百分率与实施例1获得的SA对HT-29的细胞凋亡百分率相似。
实施例6 SA对人结直肠癌细胞HT-29荷瘤小鼠体内的抗癌作用
1、试验药物的配制
HK的纯度在99%以上,购自美伦生物技术有限公司。(Dalian,China)。FBS、DMEM培养基和青霉素-链霉素液(100×)购自上海方克工业有限公司(上海,中国),所有其他溶剂和试剂均未经进一步纯化。
2、试验仪器
SPF级BALB/C裸小鼠购买于北京斯贝福生物科技有限公司。小鼠饲养条件:恒定温度(23℃)、恒定相对湿度(50%),无特定病原体的空气洁净层流架内。小鼠的饲养盒、垫料、饲料和饮用水等均经过灭菌处理,并适时更换。实验动物在实验过程中自由饮食、饮水,每日光照和黑暗各12h。
3、试验试剂
HT-29细胞(ATCC),DMSO(BD),PBS(BD),DMEM培养基(Gibco),胎牛血清(大连美伦)。
3、试验方法
人结直肠癌裸鼠移植模型建立
人结直肠癌细胞HT-29培养于直径为10cm的细胞培养皿中,待细胞长至铺满约90%培养皿底面后,弃去上清,用PBS缓冲液洗涤细胞一次,加入胰酶消化细胞,1200×g离心5min,弃去上清,用PBS缓冲液洗涤细胞两次,1200×g离心5min收集细胞,用PBS缓冲液重悬细胞,调整细胞密度为1.0×107/ml,与基质胶1:1混合后,在无菌条件下,按照每只200μl(即1.0×106)在裸鼠左侧腋窝皮下注射细胞悬液,形成皮丘,裸鼠24只,随机分为3组,每组8只(体重20-22g),3组分别为空白对照组(CTRL),HK组,SA组(实施例1制备)
4、试验结果
见图3。
将SA与药学可接受的辅料,用常规技术制备成注射剂、片剂、胶囊剂、滴丸剂或软膏剂,用于具体剂型的抗癌药的制备。
虽然,上文中已经用一般性说明及具体实施方式对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (6)
1.和厚朴酚小分子自主装纳米粒的制备方法,其特征在于包括以下步骤:将和厚朴酚溶解于pH=10-12的碱水溶液中,在70-80℃搅拌50-70分钟;转入到透析袋中,在去离子水中透析8-24小时,每1-2小时换去离子水一次,除去游离的和厚朴酚;收集透析袋内液体,干燥,获得和厚朴酚小分子自主装纳米粒。
2.根据权利要求1所述的制备方法,其特征是所述碱为NaOH或KOH。
3.权利要求1或2的制备方法制备的和厚朴酚小分子自主装纳米粒。
4.权利要求3的和厚朴酚小分子自主装纳米粒在制备抗癌药中的应用。
5.包含权利要求3所述和厚朴酚小分子自主装纳米粒的制剂。
6.根据权利要求4所述制剂,其特征是所述制剂的剂型为注射剂、片剂、胶囊剂、滴丸剂或软膏剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210539715.9A CN114848615A (zh) | 2022-05-18 | 2022-05-18 | 和厚朴酚小分子自主装纳米粒及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210539715.9A CN114848615A (zh) | 2022-05-18 | 2022-05-18 | 和厚朴酚小分子自主装纳米粒及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114848615A true CN114848615A (zh) | 2022-08-05 |
Family
ID=82640034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210539715.9A Pending CN114848615A (zh) | 2022-05-18 | 2022-05-18 | 和厚朴酚小分子自主装纳米粒及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114848615A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726067A (zh) * | 2023-07-24 | 2023-09-12 | 中国人民解放军空军特色医学中心 | 一种自组装微沉淀组合物及其皮肤用凝胶、制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103705469A (zh) * | 2014-01-03 | 2014-04-09 | 中国医学科学院药用植物研究所 | 一种和厚朴酚纳米粒及其制备方法 |
CN103877066A (zh) * | 2014-02-21 | 2014-06-25 | 中国人民解放军第二军医大学 | 载多西他赛和莱菔硫烷的自组装纳米粒的制备方法与应用 |
CN113244234A (zh) * | 2021-05-25 | 2021-08-13 | 中国药科大学 | 一种金色酰胺醇酯-半枝莲碱-棕榈酸酯自组装纳米粒及其制备方法和应用 |
-
2022
- 2022-05-18 CN CN202210539715.9A patent/CN114848615A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103705469A (zh) * | 2014-01-03 | 2014-04-09 | 中国医学科学院药用植物研究所 | 一种和厚朴酚纳米粒及其制备方法 |
CN103877066A (zh) * | 2014-02-21 | 2014-06-25 | 中国人民解放军第二军医大学 | 载多西他赛和莱菔硫烷的自组装纳米粒的制备方法与应用 |
CN113244234A (zh) * | 2021-05-25 | 2021-08-13 | 中国药科大学 | 一种金色酰胺醇酯-半枝莲碱-棕榈酸酯自组装纳米粒及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
HAIXIA JI等: ""Natural Small Molecules Enabled Efficient Immunotherapy through Supramolecular Self-Assembly in P53-Mutated Colorectal Cancer"", 《ACS APPL. MATER. INTERFACES》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726067A (zh) * | 2023-07-24 | 2023-09-12 | 中国人民解放军空军特色医学中心 | 一种自组装微沉淀组合物及其皮肤用凝胶、制备方法和应用 |
CN116726067B (zh) * | 2023-07-24 | 2024-04-16 | 中国人民解放军空军特色医学中心 | 一种自组装微沉淀组合物及其皮肤用凝胶、制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency | |
Dian et al. | Enhancing oral bioavailability of quercetin using novel soluplus polymeric micelles | |
Ji et al. | Curcumin-loaded mixed micelles: Preparation, characterization, and in vitro antitumor activity | |
Fan et al. | Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer | |
Fan et al. | Nanocrystal technology as a strategy to improve drug bioavailability and antitumor efficacy for the cancer treatment | |
Yuan et al. | Preparation of cholesteryl-modified aminated pullulan nanoparticles to evaluate nanoparticle of hydrophobic degree on drug release and cytotoxicity | |
CN105997943B (zh) | 一种人血清白蛋白负载喜树碱类药物的纳米颗粒及其制备方法和应用 | |
Lumen et al. | Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics | |
CN114848615A (zh) | 和厚朴酚小分子自主装纳米粒及制备方法 | |
Yahya Hanafi-Bojd et al. | Co-delivery of epirubicin and siRNA using functionalized mesoporous silica nanoparticles enhances in vitro and in vivo drug efficacy | |
CN107324308B (zh) | 一种核壳结构的介孔碳纳米粒及用作紫杉醇载体的用途 | |
Li et al. | Effect of a drug delivery system made of quercetin formulated into PEGylation liposomes on cervical carcinoma in vitro and in vivo | |
CN107137350A (zh) | 一种紫杉醇聚合物胶束及其制备方法 | |
CN107970242B (zh) | 一种负载紫杉醇/厄洛替尼的介孔二氧化硅-透明质酸混合靶向纳米颗粒 | |
Eroglu | A resveratrol-loaded poly (2-hydroxyethyl methacrylate)-chitosan based nanotherapeutic: characterization and in vitro cytotoxicity against prostate cancer | |
CN107137349B (zh) | 一种藤黄酸纳米混悬剂及其制备方法 | |
CN116350800A (zh) | 葡萄糖氧化酶-金属-姜黄素自组装纳米颗粒的制备与应用 | |
CN105343006A (zh) | 一种载难溶性药物的纳米骨架系统及其制备方法和应用 | |
CN105796495B (zh) | 一种盐酸伊立替康脂质体药物组合物及其制备方法 | |
Liu et al. | Enhancing oral bioavailability by paclitaxel polymeric micelles: Role of transmembrane pathways in the oral absorption | |
CN113133987A (zh) | 一种用于替尼类药物的超长循环纳米载体的制备方法 | |
CN106822906B (zh) | 水分散性酸响应淋巴靶向缓释载体纳米炭、制备方法及应用 | |
CN107812189B (zh) | 一种主动靶向特定肿瘤细胞的竹红菌素纳米制剂及其制备方法和应用 | |
CN112999197A (zh) | 一种促五环三萜类药物吸收的壳聚糖包覆固体脂质纳米粒及其制备方法 | |
Alayoubi et al. | Entrapment into nanoemulsions potentiates the anticancer activity of tocotrienols against the highly malignant (+ SA) mouse mammary epithelial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220805 |
|
WD01 | Invention patent application deemed withdrawn after publication |